Core Viewpoint - Tongrentang Yiyang has decided to delay its global offering and listing on the Hong Kong Stock Exchange due to various factors, including current market conditions [2][5]. Group 1: Listing Delay - The company announced the delay just days before its planned listing on March 30, citing multiple factors, including the current market situation [2][8]. - The decision to delay is not uncommon in the Hong Kong market, with several other companies having experienced similar situations [7]. Group 2: Subscription Data - Subscription data for Tongrentang Yiyang was not favorable, with a financing subscription multiple of only 4.85 times, indicating a lack of enthusiasm among retail investors [10]. - In contrast, other companies scheduled to list on the same day, such as Huayan Robotics and Jishijiao, had significantly higher subscription multiples, exceeding 4000 times and 3300 times, respectively [12]. Group 3: Company Overview - Tongrentang Yiyang is a subsidiary of Tongrentang Group, focusing on traditional Chinese medical services and has established a network of 12 owned medical institutions and an internet hospital [17][18]. - The company aims to raise funds to expand its medical service network, enhance service capabilities, and repay certain outstanding bank loans [20]. Group 4: Financial Performance - The company's revenue for the years 2022, 2023, 2024, and the first nine months of 2025 were reported as 911 million, 1.153 billion, 1.175 billion, and 858 million RMB, respectively [19]. - The profit figures for the same periods were approximately -9.23 million, 42.63 million, 46.2 million, and 24 million RMB [19].

Company Overview - Zhida Technology is a company specializing in home electric vehicle charging stations, holding the largest market share in China at 13.6% and a global market share of 9.0% [6][7] - The company has been operating at a loss since its inception in 2010, with revenues declining due to price wars [6][7] Financial Performance - Zhida Technology's revenues for 2022, 2023, and 2024 were recorded at CNY 697 million, CNY 671 million, and CNY 593 million respectively [6][7] - The net losses for the same years were CNY 25 million, CNY 58 million, and CNY 236 million, with further losses of CNY 32 million and CNY 17 million for the first three months of 2024 and 2025 [7] Market Activity - Zhida Technology's IPO saw a subscription rate of 5,440 times, ranking fifth among new stocks this year [6] - The final offering price was set at the lower end of the range at HKD 66.92 per share, raising approximately HKD 400 million, with a net amount of about HKD 326 million after expenses [7] Comparison with Other Companies - Jin Ye International Group, another newly listed company, achieved a subscription rate of 11,465 times, making it the highest in 2025 [4][6] - Despite a significant increase of 464% in its stock price, Jin Ye International Group's total market capitalization remains around HKD 1.1 billion [6]

Group 1 - The Hong Kong stock market has shown active performance from May 19 to May 23, with significant interest and capital inflow in the pharmaceutical and biotechnology sectors [1][2] - On May 23, the Hang Seng Index closed at 23,601.26 points, up 56.95 points or 0.24%, with a total turnover of 203.67 billion HKD for the day [1] - The pharmaceutical sector was a market highlight, particularly with the strong debut of Jiangsu Hengrui Medicine Co., Ltd., which had an IPO price of 44.05 HKD and saw a first-day increase of 25.2% [1][2] Group 2 - Singapore-based biotechnology company Mirae Group Holdings Limited also listed in Hong Kong, closing with a stock price increase of 28.76% and a market capitalization of 8.29 billion HKD [2] - The overall market strength was significantly supported by the listing of CATL (Contemporary Amperex Technology Co., Limited), which opened at 296 HKD and saw a first-day increase of 16%, followed by a further 10% rise the next day, closing at 322.4 HKD with a total market value of 1.47 trillion HKD [2] - The successful listings of industry leaders like CATL and Hengrui Medicine not only inject strong momentum into the Hong Kong stock market but also highlight Hong Kong's attractiveness as an international financial center for global quality enterprises [2]